Global Biologics Contract Manufacturing Market
The global biologics contract manufacturing market is estimated to be worth over USD 36.40 Bn in 2033 and is expected to grow at CAGR of 8.3% during the forecast period (2024-2033). The global biologics contract manufacturing market is witnessingan astonishing evolution, encouraged by numerousmajor factors and exhibited by the developing strategies of market players. Recent market panoramaunderlines a soaring demand for contract manufacturing services, with a specialized attention on innovative biologics, including monoclonal antibodies, gene and cell therapies, and biosimilars.
Several key players of the global biologics contract manufacturing market, such as Catalent, Lonza, Samsung Biologics, and Thermo Fisher Scientific, have been at the forefront of this change, enthusiastically investing in leading-edge manufacturing technologies and diversifying their global footprint. These companies have tactically established their presence in major regions like Asia-Pacific, capitalizing on cost benefits and the availability of a skilled workforce. Their commitment to innovative manufacturing solutions, comprising single-use bioreactors and continuous bioprocessing, epitomizes the industry's adaptability and dedication to staying at the lead of biologics manufacturing.
In addition to that, a substantial trend within the biologics contract manufacturing market is the increased focus on eco-friendly and green manufacturing practices. Key players like MilliporeSigma, a subsidiary of Merck, have been integratingenvironment-friendly methods and sourcing sustainable materials, coming along with regulatory and market trends focusing on environmental responsibility.
Furthermore, precision medicine is propelling demand for customized biologic therapies, including curative gene and cell therapies. Industry leaders, such as Boehringer Ingelheim, have been diversifying their capacities in this sphere to fulfil the growing demand for these innovative treatments. This underscores the industry's commitment to addressing unmet medical requirements and providingpersonalized medicine solutions.
Therefore, the global biologics contract manufacturing market is marked by its adaptability to the evolving needs of the biopharmaceutical industry. It encompasses a diverse array of biologics, innovative manufacturing solutions, global expansion, sustainability efforts, and a focus on personalized healthcare. Leading players are actively shaping the market, positioning themselves at the forefront of this dynamic and ever-evolving sector.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report includes:
A preface providing an introduction to the full report, biologics contract manufacturing market, 2023-2033.
An outline of the systematic research methodology adopted to conduct the study on biologics contract manufacturing market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
An overview of economic factors that impact the overall biologics contract manufacturing market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
An executive summary of the insights captured during our research, offering a high-level view of the current state of the biologics contract manufacturing market and its likely evolution in the mid-to-long term.
A brief introduction to the biologics contract manufacturing, highlighting their historical background, as well as information on their types, key aspects, key challenges and the advantages of using biologics contract manufacturing.
A detailed assessment of the market landscape of biologics contract manufacturing that are either approved or being evaluated in different stages of development, based on several relevant parameters, such as by Service (Manufacturing, Formulation and Fill-Finish, Packaging and Labeling, Other Services), By Type (Biologic Drug Substance Manufacturing, Biologic Drug Product Manufacturing), By Scale of Operation (Commercial Operations, Clinical Operations), By Source (Mammalian Expression Systems, Non-Mammalian Expression Systems), By Molecule (Monoclonal Antibodies, Cell Therapy & Gene Therapy, Antibody-Drug Conjugates (ADCs), Vaccines, Therapeutic Peptides & Proteins, Other Molecule Types), By Therapeutic Area (Oncology, Autoimmune Diseases, Cardiovascular Diseases, Metabolic Diseases, Infectious Diseases, Neurology, Other Infectious Diseases). Further, the chapter features analysis on key niche market segments. In addition, the chapter features analysis of various biologics contract manufacturing developers, based on their year of establishment, company size, location of headquarters and most active players.
An in-depth analysis of partnerships and collaborations that have been inked between various stakeholders, since 2019, based on several relevant parameters, such as the year of partnership, type of partnership, focus of partnership, purpose of partnership, therapeutic applications and most active players (in terms of number of partnerships). It also highlights the regional distribution of partnership activity in this market.
A detailed analysis of various investments made by companies engaged in this industry, since 2019, based on several relevant parameters, such as year of funding, type of funding (grants, seed, venture capital, initial public offering, secondary offerings, private equity and debt financing), type of HPAPIs, amount invested, geography, purpose of funding, stage of development, therapeutic area, most active players (in terms of number and amount of funding instances) and leading investors (in terms of number of funding instances).
An in-depth analysis of the various biologics contract manufacturing focused initiatives undertaken by big market players, based on several relevant parameters, such as number of initiatives, year of initiative, type of initiative, purpose of initiative, focus of initiative and location of headquarters of the big pharma players.
One of the key objectives of this market report was to estimate the current market size and the future growth potential of the biologics contract manufacturing over the forecast period. Based on several parameters, such as regional analysis as well as segmental analysis rates, we have developed informed estimates of the likely evolution of the biologics contract manufacturing market over the forecast period 2023-2033. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as by Service (Manufacturing, Formulation and Fill-Finish, Packaging and Labeling, Other Services), By Type (Biologic Drug Substance Manufacturing, Biologic Drug Product Manufacturing), By Scale of Operation (Commercial Operations, Clinical Operations), By Source (Mammalian Expression Systems, Non-Mammalian Expression Systems), By Molecule (Monoclonal Antibodies, Cell Therapy & Gene Therapy, Antibody-Drug Conjugates (ADCs), Vaccines, Therapeutic Peptides & Proteins, Other Molecule Types), By Therapeutic Area (Oncology, Autoimmune Diseases, Cardiovascular Diseases, Metabolic Diseases, Infectious Diseases, Neurology, Other Infectious Diseases), key geographical regions (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) and leading players. In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.